{"id":52959,"date":"2022-09-13T16:41:27","date_gmt":"2022-09-13T15:41:27","guid":{"rendered":"https:\/\/touchoncology.com\/?post_type=media_gallery&p=52959"},"modified":"2022-09-13T16:44:36","modified_gmt":"2022-09-13T15:44:36","slug":"bernd-kasper-esmo-2022-defi-phase-3-trial-investigating-nirogacestat-versus-placebo-for-progressing-desmoid-tumors","status":"publish","type":"media_gallery","link":"https:\/\/touchoncology.com\/soft-tissue-tumours\/conference-hub\/bernd-kasper-esmo-2022-defi-phase-3-trial-investigating-nirogacestat-versus-placebo-for-progressing-desmoid-tumors\/","title":{"rendered":"Bernd Kasper, ESMO 2022: DeFi phase 3 trial investigating nirogacestat versus placebo for progressing desmoid tumors"},"content":{"rendered":"
Desmoid tumours are rare, locally aggressive soft-tissue tumours that are challenging to manage, due to lack of approved therapies, and variable presentation. Dr Bernd Kasper <\/strong>(Universit\u00e4tsmedizin Mannheim, Mannheim, Germany) joins touchONCOLOGY to discuss the phase 3 DeFi study, a global randomized, double-blind, placebo-controlled trial in adults with progressing desmoid tumours. The trial investigates nirogacestat, a novel oral gamma secretase inhibitor, that has shown antitumour activity in patients with desmoid tumours.<\/p>\n The abstract entitled ‘DeFi: A phase III, randomized controlled trial of nirogacestat versus placebo for progressing desmoid tumors<\/a>‘ Abstract LBA2, was presented at European Society for Medical Oncology (ESMO) 2022<\/a>.<\/p>\n Questions<\/strong>:<\/p>\n Disclosures<\/strong>: Bernd Kasper is a consultant for and receives grant\/research support from Springworks;\u00a0is on the advisory board for Bayer, Blueprint, Boehringer Ingelheim, Springworks, GSK, PharmaMar, and Ayala; invited Speaker for PharmaMar, Springworks, Ayala.<\/p>\n Support<\/strong>: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.<\/p>\n\n